(October 9, 2018) A study, published in JAMA Oncology, followed about 200,000 women over the course of 25 years in order to track their use of analgesics. A little over one-thousand of those women developed epithelial ovarian cancer within that time frame. Although researchers didn’t find any significant differences in risk when they evaluated aspirin … Continued
(October 2, 2018) A study by the Mayo Clinic earlier this year aimed to increase the amount of genetic counseling referrals to epithelial ovarian cancer patients by supplying patients with a Genetics Referral Toolkit. The research was funded by OCRA through the SU2C Ovarian Cancer Dream Team. The toolkit included a checklist, a way to … Continued
(September 21, 2018) In an international collaboration funded in part by OCRFA, published recently in Cell, researchers used proteomics, the large-scale study of proteins, to identify an important indicator for treatment and disease-free survival in patients with high grade serous ovarian cancer. The biomarker, known as CT45, is associated with better response to chemotherapy and … Continued
(September 19, 2018) Researchers at the University of Washington recently made a breakthrough in identifying and confirming variants of the BRCA1 mutation, a gene mutation that increases a woman’s risk of breast and ovarian cancers. Although the most common BRCA1 and BRCA2 mutations are already known to increase risk, there are thousands of variants of … Continued
(September 14, 2018) A study published in Cell Metabolism explores the use of glycogen by ovarian cancer tumor cells, specifically in an area where metastasis happens quickly, the omentum. The omentum, or fatty tissue in the abdomen, is used by the cancer cells for the energy-heavy fat cells to grow. Once that energy source is … Continued
(August 30, 2018) Researchers at Brigham and Women’s Hospital in Boston have found new clues to the origin of high-grade serous carcinoma (HGSC). The majority of women who are diagnosed with ovarian cancer have HGSC, and up to 90 percent of those cases go undetected and undiagnosed until the cancer has spread. Previous studies showed the … Continued
(August 24, 2018) A recent study, published in JAMA Oncology, shed light on non-BRCA gene associations to breast and ovarian cancers. Researchers discovered new genes and confirmed previously existing evidence by conducting a whole-exome analysis of 11,416 patients with breast, ovarian, or both cancers and compared them with 3,988 people in a control group in … Continued
(August 23, 2018) Researchers from Vanderbilt Institute for Clinical and Translational Research recently conducted a study which focused on Medicare Part B recipients, those above the age of 65 or disabled, who were eligible for genetic testing. More specifically, they looked at women who had been seen at health centers in the Southeast United States … Continued
(August 22, 2018) Several institutions in the UK recently published their project on finding patterns in DNA mutations. The tumors of 117 women, all of whom were diagnosed with high grade serous ovarian cancer, were processed by computer algorithms. Rather than looking at mutations within each DNA strand, the algorithm identified seven patterns of DNA … Continued
(July 30, 2018) Recently, two retrospective studies were published about the effects of analgesics, or pain relievers, on ovarian cancer. The information is actually a culmination of two studies, both of which have led researchers to believe that there is an association between regular use of analgesics and both reduced risk of, and increased survival … Continued
You may have seen headlines in April 2023 about Johnson & Johnson paying nearly $9 billion to tens of thousands of people who claim talcum powder caused their cancer, including ovarian cancer. Controversy around the connection between talcum powder and cancer has gone on for years and has generated thousands of lawsuits. Ovarian Cancer Research Alliance provides information … Continued
(July 12, 2018) A study involving 58,472 women between 1994 and 2015 concluded that assisted reproductive treatment, or ART, did not lead to an increased risk of ovarian cancer. Originally it was thought that the hormones used in ART would increase ovarian activity, which would in turn increase one’s risk of ovarian cancer. However, data … Continued
Get email updates about research news, action alerts, and ways to join the fight.
